Welcome to our dedicated page for Incyte SEC filings (Ticker: INCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Incyte Corporation's SEC filings document a Nasdaq-listed biopharmaceutical issuer with common stock trading under INCY and product franchises in hematology, oncology, and inflammation and autoimmunity. Form 8-K reports cover operating results, product sales trends for Jakafi and Opzelura, financial guidance, pipeline updates, and regulatory correspondence affecting drug applications.
Proxy and current-report filings also disclose board and executive changes, officer appointments, equity compensation, shareholder voting matters, executive pay, governance practices, and registered security information. These filings frame Incyte's capital structure, leadership oversight, commercial portfolio, clinical-development programs, and regulatory risks.
BAKER BROS. ADVISORS LP reported acquisition or exercise transactions in this Form 4 filing.
INCYTE CORP director representative entities report equity awards tied to Julian C. Baker’s board service. On June 8, 2026, Baker-related fund entities were granted 1,642 restricted stock units and 6,111 non-qualified stock options linked to Incyte common stock as director compensation.
The stock options carry a $100.64 strike price and expire on June 7, 2036. Both the RSUs and options vest on the earlier of June 8, 2027, the next Incyte annual stockholder meeting, or a change in control, subject to Julian C. Baker’s continued board service. The filing states Baker Bros. Advisors LP has voting and dispositive power over these awards, while Julian C. Baker and Felix J. Baker are described as having only indirect pecuniary interests through their fund and general partner ownership.
INCYTE CORP director Edmund Harrigan received new equity awards as part of his compensation. He was granted 1,642 restricted stock units that settle one-for-one into common shares, bringing his direct common stock holdings to 22,764 shares after the award.
He also received a non-qualified stock option covering 6,111 shares of common stock at an exercise price of $100.64 per share. Both the RSUs and the option vest in full on the first anniversary of the grant date, or earlier upon the next regular annual stockholder meeting or a change of control, with the option expiring on June 7, 2036.
INCYTE CORP director Paul J. Clancy received new equity awards as part of his compensation. He was granted 1,642 shares of common stock in the form of restricted stock units, which vest in full on the first anniversary of the grant date, or earlier if the next regular annual stockholder meeting occurs or there is a change of control. He also received a non-qualified stock option for 6,111 shares of common stock at an exercise price of $100.64 per share, with the same vesting schedule. Following these awards, he holds 25,383 shares of common stock directly.
Incyte Corp director Jacqualyn A. Fouse received new equity awards consisting of restricted stock units and stock options. She was granted 1,642 RSUs that vest in full on the first anniversary of the grant date, or earlier if the next regular annual stockholder meeting occurs first, or upon a change of control as defined in the RSU plan. The RSUs settle into common stock on a one-for-one basis. She also received a non-qualified stock option for 6,111 shares of common stock at an exercise price of $100.64 per share, vesting on the same schedule and expiring in 2036. Following these awards, she directly holds 20,968 shares of common stock.
INCYTE CORP director Jean Jacques Bienaimé received new equity awards consisting of restricted stock units and stock options. He was granted 1,642 RSUs that may be settled one-for-one in common stock and 6,111 non-qualified stock options with an exercise price of $100.64 per share.
The RSUs and options each vest in full on the first anniversary of the grant date or, if earlier, on the date of the next regular annual meeting of stockholders or upon a change of control, as defined in the applicable plans. Following these RSU grants, his direct common stock holdings total 24,424 shares.
INCYTE CORP director Katherine A. High reported equity compensation awards rather than open-market trading. She received 1,642 restricted stock units that each convert into one share of common stock, and these RSUs vest in full on the first anniversary of the grant, or earlier if the next regular annual stockholders’ meeting or a change of control occurs.
She was also granted a non-qualified stock option covering 6,111 shares of common stock at an exercise price of $100.64 per share, vesting on the same schedule and expiring in 2036. Following these awards, she directly holds 14,983 shares of common stock, plus the new option grant.
INCYTE CORP director Otis W. Brawley received new equity awards as part of his compensation. He was granted 1,642 restricted stock units of common stock that vest in full on the first anniversary of the grant date, or earlier upon the next annual stockholder meeting or a change of control. He also received a non-qualified stock option for 6,111 shares of common stock at an exercise price of $100.64 per share, vesting on the same schedule and expiring on June 7, 2036. Following these awards, his direct common stock holdings total 12,894 shares.
Incyte Corporation reported the results of its annual shareholder meeting held on June 8, 2026. Shareholders elected eight directors, including Julian C. Baker, Jean-Jacques Bienaimé, Otis W. Brawley, and others, each receiving substantially more “for” than “against” votes.
Shareholders also approved the compensation of the company’s named executive officers on a non-binding advisory basis, with 145,851,784 votes for, 28,078,013 against, and 290,891 abstentions, plus 11,426,181 broker non-votes. In addition, they ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 173,072,501 votes for, 12,457,655 against, and 116,713 abstentions.
INCYTE CORP Principal Accounting Officer Tray Thomas reported an exercise-and-sale transaction in company stock. On June 4, 2026, Thomas exercised a non-qualified stock option for 2,639 shares of common stock at an exercise price of $83.83 per share, then sold 2,639 shares in an open-market transaction at $100.00 per share.
After these transactions, Thomas directly holds 21,132 shares of common stock. This total includes 15,166 shares issuable from previously reported restricted stock units that have not yet vested, indicating that a large portion of the position remains tied to equity compensation awards.
Incyte Corporation has entered into a definitive agreement to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, for $1.25 billion upfront. Star Therapeutics may receive up to an additional $750 million tied to sales milestones, for total potential consideration of $2.0 billion subject to customary closing adjustments.
The deal adds VGA039, a first‑in‑class investigational monoclonal antibody in Phase 3 development for von Willebrand disease, to Incyte’s hematology portfolio. The equity acquisition is expected to close in the third quarter of 2026, pending Hart‑Scott‑Rodino review, and is expected to result in an approximate $1.25 billion R&D charge in Incyte’s third‑quarter and full‑year 2026 GAAP and non‑GAAP results.